Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.
Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.
复制标题
DOI:
10.1038/s41388-018-0545-0
复制
发表时间:
2019-03
期刊:
影响因子:
8
通讯作者:
Ciriolo MR
中科院分区:
文献类型:
--
作者:
Di Leo L;Vegliante R;Ciccarone F;Salvatori I;Scimeca M;Bonanno E;Sagnotta A;Grazi GL;Aquilano K;Ciriolo MR
Metabolic reprogramming is a typical feature of cancer cells aimed at sustaining high-energetic demand and proliferation rate. Here, we report clear-cut evidence for decreased expression of the adipose triglyceride lipase (ATGL), the first and rate-limiting enzyme of triglyceride hydrolysis, in both human and mouse-induced hepatocellular carcinoma (HCC). We identified metabolic rewiring as major outcome of ATGL overexpression in HCC-derived cell lines. Indeed, ATGL slackened both glucose uptake/utilization and cell proliferation in parallel with increased oxidative metabolism of fatty acids and enhanced mitochondria capacity. We ascribed these ATGL—downstream events to the activity of the tumor-suppressor p53, whose protein levels—but not transcript—were upregulated upon ATGL overexpression. The role of p53 was further assessed by abrogation of the ATGL-mediated effects upon p53 silencing or in p53-null hepatocarcinoma Hep3B cells. Furthermore, we provided insights on the molecular mechanisms governed by ATGL in HCC cells, identifying a new PPAR-α/p300 axis responsible for p53 acetylation/accumulation. Finally, we highlighted that ATGL levels confer different susceptibility of HCC cells to common therapeutic drugs, with ATGL overexpressing cells being more resistant to glycolysis inhibitors (e.g., 2-deoxyglucose and 3-bromopyruvate), compared to genotoxic compounds. Collectively, our data provide evidence for a previously uncovered tumor-suppressor function of ATGL in HCC, with the outlined molecular mechanisms shedding light on new potential targets for anticancer therapy.
登录
查看更多内容
影响因子:
56.9
作者:
Das, Suman K.;Eder, Sandra;Hoefler, Gerald
通讯作者:
Hoefler, Gerald
影响因子:
56.9
作者:
Haemmerle, G;Lass, A;Zechner, R
通讯作者:
Zechner, R
影响因子:
11.2
作者:
Doherty JR;Yang C;Scott KE;Cameron MD;Fallahi M;Li W;Hall MA;Amelio AL;Mishra JK;Li F;Tortosa M;Genau HM;Rounbehler RJ;Lu Y;Dang CV;Kumar KG;Butler AA;Bannister TD;Hooper AT;Unsal-Kacmaz K;Roush WR;Cleveland JL
通讯作者:
Cleveland JL
影响因子:
7.7
作者:
Khan SA;Sathyanarayan A;Mashek MT;Ong KT;Wollaston-Hayden EE;Mashek DG
通讯作者:
Mashek DG
影响因子:
2
作者:
Grace, Shane A.;Meeks, Marshall W.;Lai, Jin-Ping
通讯作者:
Lai, Jin-Ping